Welcome to our dedicated page for Monte Rosa Therapeutics SEC filings (Ticker: GLUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biotechnology company developing molecular glue degrader (MGD) medicines, Monte Rosa uses SEC reports to describe its clinical programs, collaborations, and financial condition.
Among the most informative documents for GLUE are current reports on Form 8-K, which the company uses to announce material events such as interim clinical data, financial results, and collaboration updates. For example, Monte Rosa has furnished 8-Ks summarizing positive interim Phase 1/2 data for MRT-2359 in metastatic castration-resistant prostate cancer and reporting quarterly financial results and business updates, including progress on MRT-8102, MRT-6160, and its partnerships with Novartis and Roche.
Investors can also reference Monte Rosa’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which the company cites in its forward-looking statements as sources of detailed risk factors and operational information. These periodic filings typically include descriptions of the QuEEN™ discovery engine, the status of key programs such as MRT-8102, MRT-2359, and MRT-6160, and the structure of collaboration and license agreements.
On Stock Titan, GLUE filings are updated in near real time as they appear in the SEC’s EDGAR system. AI-powered tools help summarize lengthy documents, highlight key sections on clinical development, collaboration revenue, and cash runway, and make it easier to locate items on topics such as interim trial results, planned Phase 2 studies, or changes in capital structure. Users can quickly review Form 8-K disclosures about material events alongside the underlying press releases and presentations referenced in those filings.
Monte Rosa Therapeutics, Inc. is offering 11,125,000 shares of common stock and pre-funded warrants to purchase 1,375,000 shares at $24.00 per share (or $23.9999 per pre-funded warrant). The deal is underwritten, includes a 30‑day option for underwriters to buy up to 1,875,000 additional shares, and is expected to deliver approximately $281.6 million in net proceeds, or about $323.9 million if the option is fully exercised. After this financing, the company expects its cash, cash equivalents and marketable securities to fund operations into 2029.
Management plans to use the cash to advance lead candidate MRT-8102 in chronic inflammatory diseases including ASCVD, and to further develop and deploy its QuEENTM molecular glue degrader discovery platform across immunology, inflammation and oncology targets, as well as for general corporate purposes. The pre-funded warrants have a de minimis $0.0001 exercise price, no expiry, ownership caps between 4.99% and 19.99%, and will not be listed, while investors in this offering will experience immediate and substantial dilution versus net tangible book value.
Versant-affiliated funds reported a lower ownership stake in Monte Rosa Therapeutics, Inc. In Amendment No. 6 to their Schedule 13D, the reporting persons disclose aggregate beneficial ownership of 3,250,069 shares of Common Stock, representing 4.99% of the company’s outstanding shares, based on 65,117,761 shares outstanding as of October 31, 2025. The holdings consist of 2,236,708 shares held by Versant Venture Capital VI, L.P. and 1,013,361 shares held by Versant Vantage I, L.P.
The filing details recent activity, including several open-market sales and pro rata distributions to limited partners. Versant VI sold 15,200 shares at a weighted average price of $14.2503 on November 19, 2025, 10,205 shares at $17.64 on December 16, 2025, and 572,526 shares at a weighted average price of $23.3304 on January 7, 2026. Versant VI also distributed 500,030 shares to its limited partners on December 4, 2025, and Versant Vantage I distributed 560,092 shares on January 8, 2026, both on a pro rata basis without additional consideration.
Monte Rosa Therapeutics, Inc. President & CEO Markus Warmuth reported open-market sales of company common stock on January 7, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on May 14, 2025. He sold 3,707 shares at a weighted average price of $23.2422, 1,450 shares at $23.8762, and 309 shares at $24.5736, for a total of 5,466 shares sold.
The filing notes that each weighted average price reflects multiple trades, with sale prices ranging from $22.42 to $24.65. After these transactions, Warmuth beneficially owned 618,937 shares of Monte Rosa common stock in direct ownership.
Monte Rosa Therapeutics filed an amended Form 144 notice covering a planned stock sale. The filing indicates a proposed sale of 5,466 shares of common stock through broker Rockefeller Capital Management on the NASDAQ, with an approximate sale date of January 7, 2026.
The securities to be sold stem from a restricted stock unit (RSU) stock award for 21,865 units, acquired on January 2, 2025 from the issuer as compensation, with the payment date listed as January 2, 2026.
The document also reports that seller Markus Warmuth sold 10,135 Monte Rosa Therapeutics shares on January 5, 2026, generating gross proceeds of $153,759.
GLUE filed a Rule 144 notice for a planned stock sale. The filing covers a proposed sale of 5,466 shares of common stock through Rockefeller Capital Management, with an aggregate market value of $128,372.00. The shares are expected to be sold on or about January 7, 2026 on the NASDAQ, and the issuer had 65,117,761 shares outstanding.
The securities to be sold are tied to a stock award of 21,865 RSUs acquired on January 2, 2025 from the issuer as compensation, with a stated payment date of January 2, 2026. The person on whose behalf the sale is planned represents that they do not know of any material adverse, nonpublic information about the issuer’s current or prospective operations, and the form allows for reliance on a Rule 10b5-1 trading plan if such a plan date is indicated.
Monte Rosa Therapeutics, Inc. reported that, effective January 7, 2026, it terminated the sales agreement prospectus used for its at-the-market (“ATM”) equity program under its Form S-3 registration statement. This means the company will not sell additional shares of its common stock under the existing Open Market Sale Agreement with Jefferies LLC unless and until it files a new prospectus, prospectus supplement, or a new registration statement.
The underlying Sales Agreement with Jefferies LLC, originally dated July 1, 2022 and amended March 20, 2025, remains in full force and effect apart from the ATM prospectus termination. As of January 7, 2026, the company had issued and sold 2,955,082 shares of common stock under this arrangement, generating aggregate net proceeds of $24.2 million.
Monte Rosa Therapeutics, Inc. is conducting an underwritten public offering of $200,000,000 of common stock and, for certain investors, pre-funded warrants to purchase common shares. The pre-funded warrants are priced at the common share offering price minus $0.0001 and have a $0.0001 exercise price per share, with no expiration and optional cashless exercise.
The company’s common stock trades on the Nasdaq Global Select Market under the symbol “GLUE,” while the pre-funded warrants will not be listed and are expected to have limited liquidity. Net proceeds, together with existing cash, cash equivalents and marketable securities, are intended to fund advancement of MRT-8102 in chronic inflammatory diseases including ASCVD, further development and use of the QuEEN platform for additional molecular glue degraders, and working capital and general corporate purposes. With proceeds from this deal, Monte Rosa currently expects to fund operations into 2029, compared with funding through 2028 without this offering. As of September 30, 2025, 61,790,239 common shares were outstanding.
Monte Rosa Therapeutics reported positive interim results from an ongoing Phase 1 study of MRT-8102, a NEK7-directed molecular glue degrader being developed for inflammatory conditions linked to the NLRP3 inflammasome, IL-1, and IL-6.
Single ascending dose cohorts enrolled 48 subjects and multiple ascending dose cohorts enrolled 40 subjects, with 24 higher-risk cardiovascular subjects completing four weeks of dosing. Across study parts, MRT-8102 produced rapid, deep and sustained NEK7 degradation of about 80–90% in peripheral blood T cells at all dose levels.
MRT-8102 led to significant reductions in high-sensitivity CRP after single and seven-day multiple dosing. In subjects with elevated cardiovascular disease risk, four weeks of treatment reduced hsCRP by 85%, while the placebo group showed no significant change, and 94% of subjects reached hsCRP below 2 mg/L from a median baseline of 6.3 mg/L. The drug also reduced IL-1β secretion and endogenous IL-6, including a 55% median IL-6 drop in high-CRP subjects and a 75% decrease in cerebrospinal fluid IL-6 in two subjects.
The safety profile to date was described as favorable, with mild to moderate, self-resolving adverse events, no dose-dependent increase in frequency or severity, and no evidence of higher infection risk. Monte Rosa also outlined 2026 milestones, including Phase 2 starts and additional IND submissions across its immunology, inflammation, and oncology pipelines.
Monte Rosa Therapeutics reported positive interim results from a Phase 1/2 study of MRT-2359 plus enzalutamide in heavily pretreated metastatic castration-resistant prostate cancer. Among 20 patients enrolled, safety was favorable, with mainly mild or moderate gastrointestinal side effects.
Of 14 evaluable patients with non-neuroendocrine disease, 4 had androgen receptor mutations and all 4 achieved PSA responses, including 2 PSA90 responses. Two partial tumor responses were seen in this AR-mutant subset, giving a 100% disease control rate, while overall disease control among evaluable patients was 64% (9 of 14). Monte Rosa plans a Phase 2 study in up to 25 patients with AR-mutant disease anticipated to start in 2026 and expects to share updated MRT-2359 data at the ASCO Genitourinary Cancers Symposium in February.
The company also highlighted MRT-8102, a first-in-class NEK7-directed degrader for inflammatory diseases, with Phase 1 dosing underway in a cardiovascular risk cohort and interim data planned for early 2026.
Monte Rosa Therapeutics (GLUE) reported Q3 2025 results. Collaboration revenue was $12.8 million, up from $9.2 million a year ago. Operating expenses were $45.7 million, driven by R&D of $36.7 million and G&A of $9.1 million, resulting in a net loss of $27.1 million for the quarter.
Year to date, the company recorded net income of $7.5 million, reflecting recognition tied to collaboration activity, including completion of the $150.0 million upfront under the 2024 Novartis license. Cash, cash equivalents and marketable securities totaled $391.3 million as of September 30, 2025, with positive operating cash flow of $20.2 million for the nine-month period.
Deferred revenue was $136.7 million (current $24.8 million; noncurrent $111.9 million), supported by major partnerships. The Sept. 2025 Novartis agreement added a $120.0 million upfront (with up to $5.4 billion in potential milestones), of which $0.4 million has been recognized and $119.6 million deferred. Under the Roche collaboration, $44.9 million has been recognized to date with $17.1 million remaining deferred. Management expects existing liquidity to fund operations for at least 12 months.